Nutex Health, Inc. (NUTX) - Stock Analysis
Last updated: Mar 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Outstanding 225.5% revenue growth YTD, positive net income, expanding EBITDA margins reaching 35%, strong cash flow and liquidity, combined with sustained technical momentum (+9% price gain) support NUTX as a hot idea despite ongoing legal risks requiring monitoring.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High cash generation ⢠Strong margins ⢠Leverage & receivables NUTX delivers robust cash generation and high returns with attractive multiples but faces material solvency and earningsâquality risks from high leverage, concentrated receivables and large noncontrollingâinterest allocations.
Price Behavior
Key Price Behavior Insights: ⢠Broken support ⢠Below average ⢠Gap risk Support Level: $99â$105 Resistance Level: $110â$118 Over the last month NUTX moved into a short-term downtrend, breaking below prior support around $99â$105 and dropping from $117.60 to $90.28 (now beneath the ~$104.50 last-month average), signaling bearish momentum with resistance near $110â$118 and possible support only in the low $80s.
Sentiment & News
Key News Insights: ⢠Robust earnings ⢠Receivables overhang ⢠Legal scrutiny Nutex reported strong FY2025 revenue, earnings and a buyback while facing a $387M receivables overhang linked to potential No Surprises collections and two securities-law investigations.
AI Summary
Nutex's business shows strong margins and nearâterm FCF but the investment case is now dominated by concentrated receivables and material disclosure/internalâcontrol and litigation risks that can rapidly swing cash flow and valuation, so investors should withhold long exposure until receivable realizability (legislative enforcement or cash collections) and control remediation are credibly resolved. If receivables convert quickly and audits clear without restatements, expect a sharp positive rerating; if not, downside from writeâdowns, litigation costs, or refinancing stress is likely.
Description
Nutex Health, Inc. is a Houston-based, technology-enabled healthcare services company with two operating segments: a Hospital division that owns and operates 21 facilities across eight states, including micro-hospitals, specialty hospitals and hospital outpatient departments; and a Population Health Management division that manages provider networks and delivers management and administrative support to affiliated hospitals and physician groups. The population health unit also maintains a proprietary cloud platform that consolidates clinical and administrative data from multiple systems to provide a comprehensive view of patients and providers and to support care delivery.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 31 | Jan 7 | NUTX | Nutex Health, Inc. | Outstanding 225.5% revenue growth YTD, positive net income, expanding EBITDA margins reaching 35%, strong cash flow and liquidity, combined with sustained technical momentum (+9% price gain) support NUTX as a hot idea despite ongoing legal risks requiring monitoring. | Closed | +8.2% |